Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: EAU Guidelines on the Management of Non-neurogenic Male L… 2026 · sources last checked 2026-08-20

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

BPH / male LUTS selector

Choose the guideline lens (CUA / AUA / EAU), the IPSS tier, predominant symptoms and prostate size — get the plan: watchful waiting (mild), alpha-blocker (voiding), 5-ARI or combination (enlarged + progression), tadalafil (with ED), mirabegron/antimuscarinic (storage), and referral for complications.

Guideline lens

Symptom severity (IPSS)choose one

Predominant symptomschoose one

Prostate sizechoose one

TRUS, or DRE / PSA >1.5 as a proxy

Priorities

Flags

Symptom tier

Moderate (IPSS 8–19)

5-ARI eligibility threshold

Enlarged prostate >30 cc (or PSA >1.5 / palpable) — not met

Notes

  • • CUA/AUA use a >30cc (or PSA >1.5 / palpable) threshold for 5-ARIs; when a measured prostate volume isn't available in primary care, a DRE estimate or PSA >1.5 is an accepted proxy. PSA drawn for BPH is dual-purpose — counsel about incidental cancer case-finding (Canada does not do routine PSA screening).

Suggested drug classesPer CUA (Canada) 2022.

Select the IPSS tier and predominant symptoms to begin.

Switch the lens to see the 5-ARI size threshold (CUA/AUA >30cc vs EAU >40mL) and the antimuscarinic PVR cutoff change.

Guidelines

References

  1. [1]Elterman D, et al. UPDATE — Canadian Urological Association guideline: Male LUTS / BPH. CUAJ 2022 (5-ARI threshold >30cc; DRE/PSA proxy; combination MTOPS/CombAT). link
  2. [2]AUA Guideline: Management of LUTS Attributed to BPH — 2023 Amendment. J Urol 2023 (5-ARI >30cc; mirabegron+alpha-blocker; MIS devices). link
  3. [3]EAU Guidelines on the Management of Non-neurogenic Male LUTS, 2026 refresh (5-ARI threshold >40mL; antimuscarinic PVR cutoff 150mL; IFIS with alpha-blockers). link